The probability of undetected wild poliovirus circulation after apparent global interruption of transmission

American Journal of Epidemiology

Volumn 175, Issue 9, 2012, Pages 936-949

  Kalkowska, Dominika A ^a,b   Duintjer Tebbens, Radboud J ^a   Thompson, Kimberly M ^a  

^a Kid Risk Inc   (United States)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

disease outbreaks; disease transmission, infectious; models, statistical; poliomyelitis; poliovirus; risk assessment; surveillance; vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; ORAL POLIOMYELITIS VACCINE;

DISEASE TRANSMISSION; HEALTH POLICY; INFECTIOUS DISEASE; NUMERICAL MODEL; POLICY MAKING; POLIOMYELITIS; RISK ASSESSMENT; SEASONALITY; VACCINATION; VIRAL DISEASE;

ARTICLE; CIRCULATION; CLINICAL EFFECTIVENESS; DISEASE DURATION; DISEASE PREDISPOSITION; EPIDEMIC; HEALTH CARE POLICY; HUMAN; IMMUNITY; LIFE EXPECTANCY; MORTALITY; PARALYSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; PROBABILITY; SEROTYPE; VACCINATION; VIRUS TRANSMISSION;

COMPUTER SIMULATION; HUMANS; MODELS, THEORETICAL; POLIOMYELITIS; POLIOVIRUS;

POLIOVIRUS;

EID: 84860570820     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr399     Document Type: Article

References (44)

1. Bernier RH. Some observations on poliomyelitis lameness surveys. Rev Infect Dis. 1984;6(suppl 2):S371-S375.
2. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine (live). In: Plotkin SA, OrensteinWA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: WB Saunders/Elsevier; 2008:631-686.
3. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172(11):1213-1229.
4. Duintjer Tebbens RJ, PallanschMA, Kew OM, et al. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol. 2005;162(4):358-372.
5. Cuba IPV Study Collaborative Group. Randomized, placebocontrolled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med. 2007;356(15):1536-1544.
6. Onorato IM, Modlin JF, McBean AM, et al. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis. 1991;163(1):1-6.
7. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004;292(14):1696- 1701.
8. Andrus JK, Strebel PM, de Quadros CA, et al. Risk of vaccineassociated paralytic poliomyelitis in Latin America, 1989-91. Bull World Health Organ. 1995;73(1):33-40.
9. Kohler KA, Banerjee K, Gary Hlady W, et al. Vaccineassociated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Organ. 2002;80(3):210-216.
10. Esteves K. Safety of oral poliomyelitis vaccine: results of aWHOenquiry. BullWorld Health Organ. 1988;66(6):739-746.
11. Estívariz CF, Watkins MA, Handoko D, et al. A large vaccinederived poliovirus outbreak on Madura Island-Indonesia, 2005. J Infect Dis. 2008;197(3):347-354.
12. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296(5566):356-359.
13. Kew OM, Wright PF, Agol VI, et al. Circulating vaccinederived polioviruses: current state of knowledge. Bull World Health Organ. 2004;82(1):16-23.
14. Yang CF, Naguib T, Yang SJ, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol. 2003;77(15):8366-8377.
15. Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587-635.
16. Thompson KM, Tebbens RJ, Pallansch MA, et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health. 2008;98(7):1322-1330.
17. World Health Organization. Global Polio Eradication Initiative-Strategic Plan 2010-2012. Geneva, Switzerland: World Health Organization; 2010.
18. Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471-1505.
19. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Medscape J Med. 2008; 10(8):190.
20. Aylward RB, Sutter RW, Heymann DL. OPV cessation-the final step to a "polio-free" world. Science. 2005;310(5748): 625-626.
21. World Health Organization. Cessation of Routine Oral Polio Vaccine (OPV) Use After Global Polio Eradication: Framework for National Policy Makers in OPV-using Countries. Geneva, Switzerland: World Health Organization; 2005.
22. Smith J, Leke R, Adams A, et al. Certification of polio eradication: process and lessons learned. Bull World Health Organ. 2004;82(1):24-30.
23. World Health Organization. Global Polio Eradication Initiative: Strategic Plan 2004-2008. Geneva, Switzerland: World Health Organization; 2004.
24. Hull BP, Dowdle WR. Poliovirus surveillance: building the global polio laboratory network. J Infect Dis. 1997;175(suppl 1): S113-S116.
25. World Health Organization. Polio Laboratory Manual. 4th ed. Geneva, Switzerland: World Health Organization; 2004. (http://www.who.int/immunization- monitoring/laboratory-polio-resources/en/index.html). (Accessed May 14, 2011).
26. International Commission for the Certification of Poliomyelitis Eradication. Third Meeting of the International Commission for the Certification of Poliomyelitis Eradication (ICCPE). Final Report-Conclusions and Recommendations. Washington, DC, 22-25 August 1994. Washington, DC: Pan American Health Organization; 1994.
27. Regional Commission for the Certification of Poliomyelitis in theWestern Pacific Region,World Health Organization. Report. Sixth Meeting of the Regional Commission for the Certification of Poliomyelitis in the Western Pacific Region. Kyoto, Japan, 27-28 October 2000. Geneva, Switzerland: World Health Organization; 2000. (http://www.wpro.who.int/internet/resources.ashx/EPI/docs/ Meetings/RCC/MTGRPT-RCC6.pdf). (Accessed August 11, 2011).
28. European Regional Commission for the Certification of Poliomyelitis Eradication, World Health Organization. Fifteenth Meeting of the European Regional Commission for the Certification of Poliomyelitis Eradication. Copenhagen, Denmark, 19-21 June 2002. Geneva, Switzerland: World Health Organization; 2005. (http://www.euro.who.int/-data/assets/pdf-file/0003/79374/ E88105.pdf). (Accessed August 11, 2011).
29. Debanne SM, Rowland DY. Statistical certification of eradication of poliomyelitis in the Americas. Math Biosci. 1998;150(1): 83-103.
30. Progress toward poliomyelitis eradication-poliomyelitis outbreak in Sudan, 2004. MMWR Morb Mortal Wkly Rep. 2005; 54(4):97-99.
31. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2007-June 2008. Wkly Epidemiol Rec. 2008; 83(36):321-338.
32. Eichner M, Dietz K. Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? Am J Epidemiol. 1996;143(8):816-822.
33. Eichner M, Hadeler KP. Deterministic models for the eradication of poliomyelitis: vaccination with the inactivated (IPV) and attenuated (OPV) polio virus vaccine. Math Biosci. 1995; 127(2):149-166.
34. Eichner M, Hadeler KP, Dietz K. Stochastic models for the eradication of poliomyelitis: minimum population size for polio virus persistence. In: Isham V, Medley GF, eds. Models for Infectious Human Diseases: Their Structure and Relation to Data. New York, NY: Cambridge University Press; 1996: 315-327.
35. Abbink F, Buisman AM, Doornbos G, et al. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis. 2005;191(6): 990-999.
36. Goffe A, Pollock TM, Shand FL. Vaccination of adults with a British oral poliomyelitis vaccine prepared from Sabin strains. Br Med J. 1961;2(5247):272-275.
37. Kogon A, Spigland I, Elveback LR, et al. Oral poliovirus vaccination in middle income families. Am J Epidemiol. 1965; 82(1):14-26.
38. Vaccine Administration Subcommittee, Japan Live Poliovaccine Research Commission. Evaluation of Sabin live poliovirus vaccine in Japan. II. Clinical, virologic and immunologic effects of vaccine in children. Jpn J Med Sci Biol. 1966;19(6):277-291.
39. Sabin AB. Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries. Br Med J (Clin Res Ed). 1986;292(6519):531-533.
40. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, et al. Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA. 1960;173(14): 1521-1526.
41. Hull HF, Ward NA, Hull BP, et al. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet. 1994; 343(8909):1331-1337.
42. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Economic analysis of the Global Polio Eradication Initiative. Vaccine. 2010;29(2):334-343.
43. Thompson KM, Wallace GS, Duintjer Tebbens RJ, et al. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep. 2012; 127(1):23-37.
44. Department of Vaccines and Biologicals, World Health Organization. Guidelines for Environmental Surveillance of Poliovirus Circulation. (Report no. WHO/V&B/03.03). Geneva, Switzerland: World Health Organization; 2003.